Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome activator complex subunit 1 (PSME1) encodes the alpha subunit of the 11S proteasome regulator, PA28. The PA28 complex is an alternative regulator of the 20S core proteasome, particularly active in the immunoproteasome, where it is involved in the processing of peptides presented by MHC class I molecules. PSME1 is induced by interferon-gamma and forms a heterohexameric ring with PA28beta subunits, enhancing the generation of class I MHC-binding peptides by altering proteasome cleavage specificity. The PA28/11S regulator is central to immune surveillance and antigen processing, though not a classic pharmaceutical target itself. Disruption of PSME1 can alter immune responses and proteostasis, with potential disease roles in cancer, immunity, and infection.
Not directly targeted by approved drugs; theoretically, modulation would affect proteasome activity and antigen presentation, possibly altering immune cell responses and proteostasis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome activator complex subunit 1 (PSME1).